December PBS changes have arrived

A large number of changes to the PBS Schedule come into effect from 1 December.

Among the highlights are:

* An expansion of the affordable treatment options for patients with asthma and COPD with the listing of Breo Ellipta.

Manufactured by GlaxoSmithKline and Theravance, Breo Ellipta is a combination of an inhaled corticosteroid - fluticasone furoate - and a long-acting bronchodilator - vilanterol - administered using the Ellipta dry powder inhaler.

Breo Ellipta is PBS listed for the treatment of asthma in Australian patients aged 12 years and over. The registered strengths for the treatment of moderate to severe asthma are 100/25mcg and 200/25mcg. It is also listed on the PBS for the treatment of COPD, at a registered strength of 100/25mcg.

Prescribing information is available here.